Skip to main content

Table 4 Comparison of antibody and antigen detection rates in acute or chronic brucellosis

From: Detection of Brucellae in peripheral blood mononuclear cells for monitoring therapeutic efficacy of brucellosis infection

Phase Therapy course Reactivity (Nb/%) Total P value Intragroup
+
Acute SAT 0 10 (100%) 0 10 0.467
1–2 31 (96.9%) 1 (3.1%) 32
≥3 26 (100%) 0 26
  Overall 67 (98.5%) 1 (1.5%) 68
ELISA 0 9 (90%) 1 (10%) 10 0.209
  1–2 30 (93.8%) 2 (6.2%) 32
  ≥3 26 (100%) 0 26
  Overall 65 (95.6%) 3 (4.4%) 68
IFS 0 7 (70%) 3 (30%) 10 0.038*
1–2 27 (84.4%) 5 (15.6%) 32
≥3 14 (53.8%) 12 (46.2%) 26
   Overall 48 (70.6%) 20 (29.4%) 68
Chronic SAT 0 12 (92.3%) 1 (7.7%) 13 0.061
1–2 11 (73.3%) 4 (26.7%) 15
≥3 36 (62.1%) 22 (37.9%) 58
  Overall 59 (68.6%) 27 (31.4%) 86
ELISA 0 13 (100%) 0 13 0.299
  1–2 15 (100%) 0 15
  ≥3 55 (94.8%) 3 (5.2%) 58
  Overall 83 (96.5%) 3 (3.5%) 86
IFS 0 9 (69.2%) 4 (30.8%) 13 0.988
1–2 10 (66.7%) 5 (33.3%) 15
≥3 39 (67.2%) 19 (32.8%) 58
   Overall 58 (67.4%) 28 (32.6%) 86
  1. *A significant difference was found in IFS detection rate among therapy courses 0, 1–2 and ≥ 3 (P = 0.038), or between therapy courses 0–1-2 and ≥ 3 (P = 0.017) or 1–2 and ≥ 3 (P = 0.011) from acute phase of brucellosis patients